Literature DB >> 26150915

Pleural involvement in lung cancer.

Theodora Agalioti1, Anastasios D Giannou1, Georgios T Stathopoulos1.   

Abstract

The pleural space, a sterile secluded environment in the thoracic cavity, represents an attractive metastatic site for various cancers of lung, breast and gastrointestinal origins. Whereas lung and breast adenocarcinomas could invade the pleural space because of their anatomic proximity, "distant" cancers like ovarian or gastrointestinal tract adenocarcinomas may employ more active mechanisms to the same end. A pleural metastasis is often accompanied by a malignant pleural effusion (MPE), an unfavorable complication that severely restricts the quality of life and expectancy of the cancer patient. MPE is the net "product" of three different processes, namely inflammation, enhanced angiogenesis and vascular leakage. Current efforts are focusing on the identification of cancer cell autocrine (specific mutation spectra and biochemical pathways) and paracrine (cytokine and chemokine signals) characteristics as well as host features (immunological or other) that underlie the MPE phenotype. Herein we examine the pleural histology, cytology and molecular characteristics that make the pleural cavity an attractive metastasis destination for lung adenocarcinoma. Mesothelial and tumor features that may account for the tumor's ability to invade the pleural space are highlighted. Finally, possible therapeutic interventions specifically targeting MPE are discussed.

Entities:  

Keywords:  EGFR mutations; Lung cancer; malignant pleural effusion (MPE); pleural membranes; visceral pleural invasion (VPI)

Year:  2015        PMID: 26150915      PMCID: PMC4466428          DOI: 10.3978/j.issn.2072-1439.2015.04.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  68 in total

1.  KRAS mutations: an old oncogene becomes a new predictive biomarker.

Authors:  Gregory J Riely; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2008-10-02       Impact factor: 5.568

Review 2.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

3.  Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.

Authors:  Akihito Kubo; Yasuhiro Koh; Tomoya Kawaguchi; Shun-Ichi Isa; Isamu Okamoto; Junya Fukuoka; Yoko Kusunoki; Masanori Kitaichi; Minoru Takada; Kazuhiko Nakagawa
Journal:  Intern Med       Date:  2011-04-01       Impact factor: 1.271

Review 4.  Malignant pleural effusion: tumor-host interactions unleashed.

Authors:  Georgios T Stathopoulos; Ioannis Kalomenidis
Journal:  Am J Respir Crit Care Med       Date:  2012-05-31       Impact factor: 21.405

5.  Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.

Authors:  Tomoaki Tanaka; Yoshiaki Nagai; Hitoshi Miyazawa; Nobuyuki Koyama; Suguru Matsuoka; Akihisa Sutani; Kiyoshi Udagawa; Yoshitake Murayama; Makoto Nagata; Yoshihiko Shimizu; Kenji Ikebuchi; Minoru Kanazawa; Kunihiko Kobayashi; Koichi Hagiwara
Journal:  Cancer Sci       Date:  2007-02       Impact factor: 6.716

6.  Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions.

Authors:  Jung Ok Park; Do-Young Choi; Dong-Sic Choi; Hee Joung Kim; Jeong Won Kang; Jae Hun Jung; Jeong Hwa Lee; Jayoung Kim; Michael R Freeman; Kye Young Lee; Yong Song Gho; Kwang Pyo Kim
Journal:  Proteomics       Date:  2013-07       Impact factor: 3.984

Review 7.  Malignant pleural effusion.

Authors:  A M Egan; D McPhillips; S Sarkar; D P Breen
Journal:  QJM       Date:  2013-12-24

8.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.

Authors:  C-H Gow; Y-L Chang; Y-C Hsu; M-F Tsai; C-T Wu; C-J Yu; C-H Yang; Y-C Lee; P-C Yang; J-Y Shih
Journal:  Ann Oncol       Date:  2008-12-16       Impact factor: 32.976

9.  Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer.

Authors:  Xiaozhu Zhang; Yi Zhao; Miao Wang; Wee See Yap; Alex Yuang-chi Chang
Journal:  Lung Cancer       Date:  2007-12-03       Impact factor: 5.705

Review 10.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more
  24 in total

1.  Advances and controversies in pleural diseases.

Authors:  José M Porcel; Georgios Statophoulos; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Peripheral lung adenocarcinomas harboring epithelial growth factor receptor mutations with microRNA-135b overexpression are more likely to invade visceral pleura.

Authors:  Hanbo Le; Xiaoling Wang; Yao Zha; Jie Wang; Wangyu Zhu; Zhinan Ye; Xiaoguang Liu; Haijie Ma; Yongkui Zhang
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

3.  Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.

Authors:  Mei Feng; Jing Zhu; Liqun Liang; Ni Zeng; Yanqiu Wu; Chun Wan; Yongchun Shen; Fuqiang Wen
Journal:  Int J Clin Oncol       Date:  2016-12-18       Impact factor: 3.402

4.  ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma.

Authors:  Zheng Wang; Xiaonan Wu; Xiaohong Han; Gang Cheng; Xinlin Mu; Yuhui Zhang; Di Cui; Chang Liu; Dongge Liu; Yuankai Shi
Journal:  Chin J Cancer Res       Date:  2016-12       Impact factor: 5.087

5.  Prognostic significance of FoxM1 expression in non-small cell lung cancer.

Authors:  Qing Sun; Min Dong; Yujuan Chen; Jiawei Zhang; Jinpeng Qiao; Xuedan Guo
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

6.  Patient-reported symptoms before palliative radiotherapy predict survival differences.

Authors:  Carsten Nieder; Thomas A Kämpe; Adam Pawinski; Astrid Dalhaug
Journal:  Strahlenther Onkol       Date:  2018-01-17       Impact factor: 3.621

7.  Ubiquitin Conjugating Enzyme E2 H (UBE2H) Is Linked to Poor Outcomes and Metastasis in Lung Adenocarcinoma.

Authors:  Meng-Chi Yen; Kuan-Li Wu; Yu-Wei Liu; Yung-Yun Chang; Chao-Yuan Chang; Jen-Yu Hung; Ying-Ming Tsai; Ya-Ling Hsu
Journal:  Biology (Basel)       Date:  2021-04-28

8.  IL-33 delivery induces serous cavity macrophage proliferation independent of interleukin-4 receptor alpha.

Authors:  Lucy H Jackson-Jones; Dominik Rückerl; Freya Svedberg; Sheelagh Duncan; Rick M Maizels; Tara E Sutherland; Stephen J Jenkins; Henry J McSorley; Cécile Bénézech; Andrew S MacDonald; Judith E Allen
Journal:  Eur J Immunol       Date:  2016-10       Impact factor: 5.532

9.  Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.

Authors:  Bin Li; Zhouhong Yao; Yunyan Wan; Dianjie Lin
Journal:  Oncotarget       Date:  2016-11-22

10.  Do mesothelin/MUC16 interactions facilitate adenocarcinoma metastases to intracranial meningiomas?

Authors:  Mahlon D Johnson
Journal:  Surg Neurol Int       Date:  2016-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.